InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Kairos Pharma, LTD.

KAPA Clue Score33
United States Fiscal year ends December CIK 0001962011
$0.81 -15.55% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.81 −38.61% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 16 Sep 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−1.7Net income−1.8EPS, diluted−0.17Fiscal year 2024Operating income−2.3Net income−2.6EPS, diluted−0.23Fiscal year 2025Operating income−5.6Net income−5.4EPS, diluted−0.30
FY2023FY2024FY2025
Operating income −1.7 −2.3 −5.6
Net income −1.8 −2.6 −5.4
Growth
EPS, diluted −0.17 −0.23 −0.30

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2023Operating cash flow0.1Fiscal year 2024Operating cash flow−4.0Fiscal year 2025Operating cash flow−3.4
FY2023FY2024FY2025
Operating cash flow 0.1 −4.0 −3.4

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash0.1Shareholders’ equity−2.1Fiscal year 2024Cash1.3Shareholders’ equity4.8Fiscal year 2025Cash4.5Shareholders’ equity6.3
FY2023FY2024FY2025
Cash 0.1 1.3 4.5
Shareholders’ equity −2.1 4.8 6.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −54.5% −85.9%
−187.8% −45.1% −83.3%
Balance and payout
315.3% 17.2% n/a